Tandem Gets FDA Clearance For Tubeless Mobi — Users Can Keep Their Existing Pumps
The infusion set allows up to seven days of wear, while cartridges have a three-day limit and new supplies will be pharmacy-only.
Tandem Diabetes Care, which designs and sells insulin pumps and related software, received FDA clearance Thursday to turn existing Mobi pumps into tubeless devices. The company said in an SEC filing Friday that customers can use a new cartridge and infusion set while keeping their current pump and its automated insulin-adjustment technology.
Seven-Day Wear, Three-Day Cartridges
The FDA cleared the tubeless infusion set for up to seven days of wear. The insulin cartridge has a separate limit of three days of use.
Mobi owners will be able to choose tubed or tubeless delivery without replacing the pump. Both configurations use Control-IQ+, Tandem's technology for automatically adjusting insulin dosing.
President and CEO John Sheridan said the ability to offer different ways to wear Mobi was part of its original design.
Pharmacies Get The New Supplies
Tandem's launch announcement said the tubeless supplies will be available exclusively through pharmacies for customers with pharmacy benefits. The company estimates that its pharmacy coverage reaches approximately 50% of insured U.S. lives.
The new configuration adds to a business that sells pumps alongside recurring-use supplies, including insulin cartridges and infusion sets. Tandem's Mobi and t:slim X2 pumps work with continuous glucose monitoring sensors and Control-IQ+ to automate dosing.
According to its 2025 annual report, Tandem serves nearly 500,000 people across more than 25 countries. Its pumps are assembled in San Diego, California.
Canada Expands t:slim X2 Use
Tandem also announced expanded Canadian authorization Thursday for t:slim X2. The changes add compatibility with Abbott's FreeStyle Libre 3 Plus sensor and permit use during pregnancies involving type 1 diabetes and by adults with type 2 diabetes.
The pregnancy authorization drew on trial findings published in October 2025. A randomized study of more than 300 people supported the adult type 2 authorization, with results published in March 2025.
Tandem plans a full U.S. launch of the tubeless cartridge and infusion set in the first half of 2027.
Sources
- 8-K Filing — TANDEM DIABETES CARE INC (TNDM) — SEC EDGAR
- Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump – Company Announcement - FT.com — Financial Times
- Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear — businesswire.com